Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

5
Player Avatar DarthMaul09 (29.75) Submitted: 11/4/2011 11:39:56 PM : Underperform Start Price: $9.11 DNDN Score: +9.14

Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acceptance of any treatment that cannot compete on the basis of cost. In this environment their best hope is that their stock price continues to fall to a level where a larger pharm company buys them out for their patents. This may help some of the people that work for the company but it won't help the investors.

Featured Broker Partners


Advertisement